Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire    SHP   JE00B2QKY057

SHIRE (SHP)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/12/2012 | 05:49pm CEST
  By Sten Stovall 
  Of  
 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIRE
10/19 SHIRE : Create the Soundtrack to Your Unique Day with “Compose Your Life&r..
10/18 FTSE rises to record close, blue-chips shrug off Reckitt blip
10/17 SHIRE : New Formulation of ONCASPAR Receives Positive CHMP Opinion in Europe for..
10/14 SHIRE : Activist fund seeks break-up of £35bn pharma group Shire
10/13 SHIRE PLC : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP O..
10/13 SHIRE : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opini..
10/12 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
10/12 SHIRE : to announce third quarter 2017 results
10/12DJSHIRE PLC SHIRE PLC : Notice Of Results
10/12 SHIRE PLC : Notice of Results
More news
News from SeekingAlpha
10/19 Premarket analyst action - healthcare
10/18 Generic Restasis Risk Metastasizes To Shire
10/18 Shire feels Amgen's Restasis patent pain, shares down 3%
10/16 YOUR DAILY PHARMA SCOOP : ACRX Second Chance, AERI Rhopressa Success, Aratana EN..
10/13 European advisory group backs Shire's lyophilized Oncaspar for ALL
Financials ($)
Sales 2017 14 973 M
EBIT 2017 5 586 M
Net income 2017 2 577 M
Debt 2017 19 246 M
Yield 2017 0,73%
P/E ratio 2017 16,76
P/E ratio 2018 12,05
EV / Sales 2017 4,29x
EV / Sales 2018 3,87x
Capitalization 44 964 M
Chart SHIRE
Duration : Period :
Shire Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Technical analysis trends SHIRE
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 69,0 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
Matt Walker Head-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE-20.59%44 568
JOHNSON & JOHNSON22.11%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214